【摘要】 目的探讨洛铂(LBP)、顺铂(DDP)和卡铂(Cab)单药或联合紫杉醇(PTX)、多西他赛(DOC)和长春瑞滨(NVB)抗人肺癌细胞株的作用和活性。方法选用4种人非小细胞肺癌(NSCLC)细胞株A549、NCI-H460、Calu-3、NCI-H23和小细胞肺癌(SCLC)细胞株NCI-H526,用不同浓度的LBP、DDP和Cab单独或与PTX、DOC和NVB联合处理上述肺癌细胞株72h,应用磺酰罗丹明染色法评价细胞增殖,计算半数抑制浓度(IC50)。结果 LBP、DDP和Cab单药均可抑制体外培养的肺癌细胞株生长,其中LBP对4种NSCLC细胞株的IC50为1.7～2.4μmol/L,DDP为1.8～5.2μmol/L,Cab为22.8～100.8μmol/L;LBP、DDP和Cab对SCLC细胞株的IC50分别为0.3μmol/L、0.6μmol/L和9.8μmol/L。LBP分别与PTX、DOC和NVB联合抗NSCLC细胞株有明显增效作用,其中与PTX合用的协同作用最强。DDP或Cab分别与PTX、DOC和NVB联合的抑制作用与细胞株的类型有关。结论在上述3种铂类药物中,LBP具有明确的抗NSCLC细胞作用,与DDP相似,而强于Cab,其抗癌活性与细胞株的类型无关。LBP分别联合PTX、DOC和NVB均有协同作用,其中与PTX的联合作用最强。更多还原

【Abstract】 Objective To investigate inhibitory effects of lobaplatin,cisplatin and caboplatin alone or combined with paclitaxel,docetaxel and vinorelbine against human lung cancer cell lines in vitro. MethodsFour kinds of human NSCLC cell lines A549,NCI-H460,Calu-3,NCI-H23 and one kind of human SCLC cell line NCI-H526 were cultivated,which were treated with lobaplatin,cisplatinum and carboplatin respectively in different concentrations alone or combined with paclitaxel,docetaxel,vinorelbine.Proliferation and 50% inhibitory concentration(IC50)were calculated. ResultsLobaplatin,cisplatin and carboplatin could inhibit lung cancer cell lines’ growth in vitro.IC50 in 4 NSCLC cell lines treated by lobaplatin,cisplatin and carboplatin were 1.7-2.4μmol/L,1.8-5.2μmol/L and 22.8-100.8μmol/L,respectively.IC50 in SCLC cell line treated by lobaplatin,cisplatin and caboplatin were 0.3μmol/L,0.6μmol/L and 9.8μmol/L respectively.Lobaplatin combined with paclitaxel,docetaxel and vinorelbine showed an obvious synergistic effect without antagonism,especially with paclitaxel.Cisplatin or carboplatin combined with other chemotherapeutics for different cell lines had various effects. ConclusionLobaplatin has an obvious antitumor activity in NSCLC cells in vivo,which is similar to cisplatin and better than carboplatin.Lobaplatin combined with paclitaxel,docetaxel and vinorelbine may generate a synergy inhibitory effect,especially with paclitaxel.更多还原